Mpm Bioventures sells $461,545 in Entrada Therapeutics stock

MPM BioVentures 2014, L.P., a 10% owner and director of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold $461,545 worth of the company's stock over three days in late August 2026. The stock, which trades at $7, has seen a nearly 8% decline over the past week, nearing its 52-week low of $5.02. The sales, comprising 62,614 shares sold at weighted average prices ranging from $7.06 to $7.54 per share, reduced the indirect beneficial ownership to 4,318,348 shares.

Despite the financial headwinds and a consensus Buy rating with price targets ranging from $11 to $25, the biotech company continues to advance in its research efforts, including receiving clearance to escalate the dose in its ongoing ELEVATE-45-201 study for Duchenne muscular dystrophy.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.